Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
First Claim
1. An isolated tumour associated peptide consisting of the peptide set forth in SEQ ID NO:
- 4 flanked by N- and/or C-terminal extensions from 1 to 10 amino acids in length.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the present invention relates to 49 novel peptide sequences derived from HLA class II molecules of human tumor cell lines which can be used in vaccine compositions for eliciting anti-tumor immune responses.
57 Citations
9 Claims
-
1. An isolated tumour associated peptide consisting of the peptide set forth in SEQ ID NO:
- 4 flanked by N- and/or C-terminal extensions from 1 to 10 amino acids in length.
- View Dependent Claims (2, 4, 5, 6, 7)
-
3. A fusion protein comprising a peptide set forth in SEQ ID NO:
- 4, and N-terminal amino acids of HLA-DR antigen-associated invariant chain (Ii).
- View Dependent Claims (8)
-
9. An isolated tumour associated peptide consisting of the peptide set forth in SEQ ID NO:
- 4.
Specification